Lemzoparlimab, the monoclonal antibody developed by I-Mab, is designed to treat multiple cancers. It aims to minimize inherent binding to normal red blood cells while maintaining its anti-tumor effects, a quality which could differentiate it from similar antibodies in development.
AbbVie will pay I-Mab $180 million upfront, as well as a $20 million milestone payment based on Phase 1 results. The drugmaker will also pay an additional $1.74 billion in success-based milestone payments for lemzoparlimab.
“Cancer is the second-leading cause of death globally and the need for novel cancer therapies has never been more acute. The addition of I-Mab’s novel CD47 programs complements our global clinical strategy in hematology and immuno-oncology,” Thomas Hudson, MD, AbbVie’s senior vice president of research and development and chief scientific officer, said in a news release. “We have been impressed with what I-Mab has been able to accomplish in research and clinical development and we look forward to working together to make a meaningful difference in the lives of millions of patients globally.”
More articles on pharmacy:
Samsung Biologics to open $2B drug manufacturing plant
2nd FDA appointee ousted as agency faces criticism from medical community
US decision to abstain from WHO-backed vaccine initiative ‘awkward, contradictory and self-defeating,’ expert says
AbbVie on Sept. 4 signed a $2.9 billion deal with Chinese biotech company I-Mab to develop and sell its top cancer drug.
Lemzoparlimab, the monoclonal antibody developed by I-Mab, is designed to treat multiple cancers. It aims to minimize inherent binding to normal red blood cells while maintaining its anti-tumor effects, a quality which could differentiate it from similar antibodies in development.
AbbVie will pay I-Mab $180 million upfront, as well as a $20 million milestone payment based on Phase 1 results. The drugmaker will also pay an additional $1.74 billion in success-based milestone payments for lemzoparlimab.
“Cancer is the second-leading cause of death globally and the need for novel cancer therapies has never been more acute. The addition of I-Mab’s novel CD47 programs complements our global clinical strategy in hematology and immuno-oncology,” Thomas Hudson, MD, AbbVie’s senior vice president of research and development and chief scientific officer, said in a news release. “We have been impressed with what I-Mab has been able to accomplish in research and clinical development and we look forward to working together to make a meaningful difference in the lives of millions of patients globally.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
